Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price
Fierce Pharma
Wed, 05/24/17 - 10:35 am
Tags:
Sanofi, Regeneron, Kevzara, rheumatoid arthritis
Celgene, Regeneron and Vertex execs, NIH chief head to White House as threat of Trump funding cuts looms
Fierce Biotech
Mon, 05/8/17 - 10:04 pm
Tags:
biotech, Celgene, Regeneron, Vertex Pharmaceuticals, NIH, Donald Trump
Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts
Fierce Pharma
Mon, 05/8/17 - 11:38 am
Tags:
Sanofi, Regeneron, drug launches, Dupixent, eczema
Regeneron posts mixed Q1 results, Eylea growth slows
Drug Delivery Business News
Sun, 05/7/17 - 10:13 am
Tags:
Regeneron, earnings, Eylea
5 Big Drugmakers With Important Catalysts in May
Motley Fool
Sun, 04/30/17 - 01:00 pm
Tags:
FDA, Merck, Keytruda, Isentress, Novartis, PKC412, Novo Nordisk, nonacog beta pegol, Sanofi, Regeneron, Kevzara
Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?
Market Realist
Wed, 04/26/17 - 09:40 pm
Tags:
Regeneron, earnings
Regeneron’s CEO, CSO saw their compensation slashed in ’16 — but it’s still a jaw-dropping sum
Endpoints
Tue, 04/25/17 - 11:50 pm
Tags:
Regeneron, Pharma CEOs, executive pay, Leonard Schleifer
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
Yahoo
Tue, 04/25/17 - 11:04 am
Tags:
Sanofi, Regeneron, FDA, Praluent
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
Yahoo/Reuters
Sat, 04/22/17 - 01:14 pm
Tags:
Europe, EMA, Sanofi, Regeneron, rheumatoid arthritis, Kevzara, Sarilumab
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Mon, 04/17/17 - 12:07 pm
Tags:
Eli Lilly, Inctye, AbbVie, Regeneron, rheumatoid arthritis, FDA, baricitinib, Humira
When do pharmas disclose launch prices up front? When they’re pricing at a discount
Fierce Pharma
Fri, 04/14/17 - 10:03 am
Tags:
drug discounts, drug pricing, Roche, Neurocrine, Sanofi, Regeneron, Tesaro, Novartis
3 Big Biotech Stocks With Big-Time Catalysts
Motley Fool
Sun, 04/9/17 - 12:36 pm
Tags:
Regeneron, Praluent, Amgen, biosimilars, Amjevita, Humira, ABP-215, Avastin, ABP-980, Herceptin, Celgene, ozanimod
The stellar antibody shop at Regeneron wins a ‘breakthrough’ tag for its next big PhIII drug
Endpoints
Fri, 04/7/17 - 09:48 am
Tags:
Regeneron, breakthrough therapies, evinacumab, LDL cholesterol
How a $37,000-a-year medicine sets a good model for drug pricing
Stat
Tue, 04/4/17 - 12:17 am
Tags:
drug pricing, psoriasis, Dupixent, Regeneron
Lilly, Pfizer, et al. back Sanofi and Regeneron in PCSK9 patent appeal. AbbVie doesn't
Fierce Pharma
Tue, 04/4/17 - 12:13 am
Tags:
Eli Lilly, Pfizer, Sanofi, AbbVie, Regeneron, patents, PCSK9 inhibitors, Repatha
Sarepta chief hands over CMO role to former Regeneron exec
Bizjournals.com
Tue, 04/4/17 - 12:09 am
Tags:
Sarepta Therapeutics, Regeneron, CMOs
Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster
Motley Fool
Thu, 03/30/17 - 09:39 am
Tags:
Regeneron, eczema, Sanofi, Dupixent
Can a $37,000 price be right? For Dupixent, analysts (and one payer) say yes
Fierce Pharma
Wed, 03/29/17 - 11:58 am
Tags:
drug pricing, Dupixent, Sanofi, Regeneron, eczema
As blockbuster drugs fizzle, biotech looks warily to the next big thing
Stat
Wed, 03/29/17 - 11:52 am
Tags:
biotech, Dupixent, Sanofi, Regeneron
FDA approves Regeneron, Sanofi $37,000 per year eczema drug
Yahoo/Reuters
Tue, 03/28/17 - 12:28 pm
Tags:
FDA, Dupixent, Sanofi, Regeneron, eczema

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.